Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationVida Tajiknia|American Journal of Cancer Research|2024Cited by 5
Synergistic anti-tumor activity, reduced pERK, and immuno-stimulatory cytokine profiles with 5-FU or ONC212 plus KRAS G12D inhibitor MRTX1133 in CRC and pancreatic cancer cells independent of G12D mutationVida Tajiknia, Wafik S. El‐Deiry|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 1